Peter W. Sonsini
CIK 1559807 · last filed 2022-12-22
Peter W. Sonsini is a corporate insider who has filed 87 SEC Form 4 insider transactions across 32 companies since 2014. The most recent filing, for ACLX, was dated Dec 22, 2022. Across all open-market trades the lifetime net is +$647.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $3.82B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.82B
Companies
32
Total Filings
87
Lifetime Open-Market Net
$646.98M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Arcellx, Inc. (ACLX) Delisted | 10%+ Owner | 4,850,214 | $115.07 | $558.11M | $190.00M | 2 | 2022-12-22 |
| Akouos, Inc. (AKUS) Delisted | 10%+ Owner | 0 | $13.29 | $0 | $10.00M | 2 | 2022-12-02 |
| IONQ.WS | 10%+ Owner | 0 | $22.45 | $0 | $0 | 1 | 2022-11-18 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | 10%+ Owner | 24 | $15.00 | $360 | $24.62M | 17 | 2022-10-21 |
| NeueHealth, Inc. (BHG) Delisted | 10%+ Owner | 278,608 | $16.35 | $4.56M | $35.00M | 3 | 2022-10-19 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | 10%+ Owner | 0 | $0.00 | $0 | $21.03M | 4 | 2022-05-26 |
| HOOD | Director | 30,431 | $92.76 | $2.82M | $0 | 5 | 2022-05-04 |
| TRVI | 10%+ Owner | 10,421,428 | $18.43 | $192.07M | $31.80M | 4 | 2022-04-13 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 2,734,189 | $0.49 | $1.35M | $9.51M | 2 | 2021-12-27 |
| GLUE | 10%+ Owner | 5,973,296 | $22.04 | $131.65M | $19.95M | 1 | 2021-06-30 |
| Desktop Metal, Inc. (DM) Delisted | 10%+ Owner | 5 | $4.96 | $25 | $0 | 1 | 2021-06-10 |
| Eargo, Inc. (EAR) Delisted | 10%+ Owner | 1,500 | $2.57 | $3.9K | $5.60M | 2 | 2021-05-26 |
| OnKure Therapeutics, Inc. (RPHM) Delisted | 10%+ Owner | 478,549 | $18.20 | $8.71M | $90.00M | 1 | 2021-04-15 |
| MRKR | 10%+ Owner | 1,071,428 | $1.18 | $1.26M | $10.00M | 1 | 2021-03-18 |
| Regulus Therapeutics Inc. (RGLS) Delisted | 10%+ Owner | 645,106 | $8.16 | $5.26M | $3.96M | 3 | 2020-12-07 |
| Mersana Therapeutics, Inc. (MRSN) Delisted | 10%+ Owner | 30 | $29.08 | $872 | $150.00M | 4 | 2020-09-16 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 2,187,689 | $4.00 | $8.75M | $4.00M | 1 | 2020-07-28 |
| NKTX | 10%+ Owner | 522,639 | $2.22 | $1.16M | $12.00M | 1 | 2020-07-16 |
| Surface Oncology, Inc. (SURF) Delisted | 10%+ Owner | 6,072,421 | $1.07 | $6.50M | -$10.28M | 2 | 2020-05-22 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | 10%+ Owner | 82,978,668 | $0.06 | $4.80M | $5.00M | 1 | 2020-01-28 |
| ARDX | 10%+ Owner | 3,082,186 | $5.08 | $15.67M | $23.33M | 4 | 2019-12-09 |
| MIRM | 10%+ Owner | 3,736,243 | $112.23 | $419.32M | $6.75M | 1 | 2019-07-24 |
| ASND | 10%+ Owner | 12,000,000 | $254.44 | $3.05B | $49.02M | 4 | 2018-09-10 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | 10%+ Owner | 0 | $28.80 | $0 | -$731.3K | 1 | 2018-02-27 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | 10%+ Owner | 10,882,574 | — | — | $0 | 1 | 2018-02-22 |
| APPN | 10%+ Owner | 27,581 | $27.35 | $754.3K | -$66.07M | 4 | 2018-02-15 |
| SYNLOGIC, INC. (SYBX) Delisted | 10%+ Owner | 281,929 | $0.69 | $194.5K | $0 | 2 | 2018-01-26 |
| MULESOFT, INC (MULE) Delisted | 10%+ Owner | 12,679,970 | — | — | $0 | 1 | 2017-03-22 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 5,215,128 | — | — | $13.50M | 2 | 2016-12-19 |
| Avalo Therapeutics, Inc. (CERC.U) Delisted | 10%+ Owner | 594,245 | — | — | $0 | 1 | 2015-10-20 |
| SYNLOGIC, INC. (MIRN) Delisted | 10%+ Owner | 2,082,725 | — | — | $6.00M | 1 | 2015-10-06 |
| Loxo Oncology, Inc. (LOXO) Delisted | 10%+ Owner | 1,789,420 | — | — | $3.00M | 1 | 2014-08-06 |
Recent Filings
87 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-12-22 | Arcellx, Inc. (ACLX) Delisted | Other (J) | −1,999,179 | $0 | EDGAR |
| 2022-12-02 | Akouos, Inc. (AKUS) Delisted | U | −4,294,207 | $0 | EDGAR |
| 2022-11-18 | IONQ.WS | Other (J) | −11,687,067 | $0 | EDGAR |
| 2022-10-21 | AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Other (J) | −3,951,334 | $0 | EDGAR |
| 2022-10-19 | NeueHealth, Inc. (BHG) Delisted | Buy (P) | — | $0 | EDGAR |
| 2022-05-26 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Sell (S) | −10,376,936 | -$750.7K | EDGAR |
| 2022-05-04 | HOOD | Other (J) | −23,813,965 | $0 | EDGAR |
| 2022-04-13 | TRVI | Buy (P) | +3,580,526 | $6.80M | EDGAR |
| 2022-02-09 | Arcellx, Inc. (ACLX) Delisted | Mixed | +51,462,096 | $190.00M | EDGAR |
| 2022-02-01 | HOOD | Other (J) | −23,856,861 | $0 | EDGAR |
Showing 1–10 of 87
Page 1 of 9
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.